Shionogi's S-892216 Study Targets Renal Impairment Pharmacokinetics
A study is underway to assess the pharmacokinetics, safety, and tolerability of S-892216 in patients with varying degrees of renal impairment.
Phase III
Nephrology / Pharmacokinetics
Status
Active
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
The ongoing trial of S-892216 in patients with renal impairment is significant as it addresses a critical patient population that may have unmet therapeutic needs. Positive outcomes could enhance the drug's market positioning and broaden its therapeutic applications.
Recommended action
Humanexa recommends Monitor.
Analysis
Key milestones include recruitment progress and initial safety data release from the trial.
Related companies & assets
Assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.